The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an α-cardiac myosin heavy chain missense mutation

Nature Medicine

Volumn 5, Issue 3, 1999, Pages 327-330

  Georgakopoulos, Dimitrios ^a   Christe, Michael E ^b   Giewat, Michael ^b   Seidman, Christine M ^b   Seidman, J G ^b   Kass, David A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN HEAVY CHAIN;

ADOLESCENT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE COURSE; HEART INDEX; HEART MUSCLE COMPLIANCE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HYPERTROPHIC CARDIOMYOPATHY; MISSENSE MUTATION; MOUSE; NONHUMAN; PATHOGENESIS; PRESSURE VOLUME CURVE; PRIORITY JOURNAL;

AGING; ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; DIASTOLE; DISEASE MODELS, ANIMAL; GENETIC DISEASES, INBORN; HUMANS; MICE; MUTATION, MISSENSE; MYOSIN HEAVY CHAINS; SYSTOLE;

ANIMALIA;

EID: 0033017175     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/6549     Document Type: Article

References (25)

1. Seidman, C.E. & Seidman, J.G. in Molecular Cardiovascular Medicine (ed. E. Haber, E.) 193-210 (Scientific American Press, New York, 1995).
2. Watkins, H. et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N. Engl J. Med. 326, 1108-1114 (1992).
3. Wigle, E.D., Rakowski, H,. Kimball, B.P. & Williams, W.G. Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 92, 1680-1692 (1995).
4. Bonow, R.O. et al. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. Circulation 68, 1062-1073 (1983).
5. Pak, P.H., Maughan, W.L., Baughman, K.L. & Kass, D.A. Marked discordance between dynamic and passive diastolic pressure-volume relations in idiopathic hypertrophic cardiomyopathy. Circulation 94, 52-60 (1996).
6. Pak, P.H., Maughan, W.L., Baughman, K.L., Caval, R.S. & Kass, D.A. Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart: Similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation 98, 242-248 (1998).
7. Ceisterfer-Lowrance, A.T. et al. A mouse model of familial hypertrophic cardiomyopathy. Science 272, 731-744 (1996).
8. Georgakopoulos, D et al. In vivo murine left ventricular pressure-volume relations by miniaturized conductance-micromanometry Am. J. Physiol. 274(4 Pt 2), H1416-H1422 (1998).
9. 1-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J. Pharmacol. Exp. Ther. 278, 1435-1443 (1996).
10. Suga, H. & Sagawa, K. Instantaneous pressure-volume relationships and their ratio in the excised, supported canine left ventricle. Circ. Res 35, 117-128 (1974).
11. 4+5, mouse model of familial hpertrophic cardiomyopathy. J. Clin. Invest. 101, 1775-1783 (1998).
12. Kapuku, G.K. et al. Impaired left ventricular filling in borderline hypertensive patients without cardiac structural changes. Am Heart J. 125, 1710-1716 (1993).
13. Palatini, P. et al. Structural abnormalities and not diastolic dysfunction are the earliest left ventricular changes in hypertension. Am. J. Hypertens. 11, 147-154 (1998).
14. Tardiff, J.C. et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J. Clin. Invest. 107, 2800-2811 (1998).
15. Oberst, L. et al. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J. Clin invest. 102, 1498-1505 (1998).
16. Gottshall, K.R. et al. Ras-dependent pathways induce obstructive hypertrophy in echo-selected transgenic mice. Proc. Natl. Acad. Sci. USA 94(9), 4710-4715 (1997).
17. Milano, C.A. et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 264, 582-586 (1994).
18. Grupp, I.L. et al. Overexpression of alpha-1 adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy, Am. J. Physiol. 275(4 Pt 2), H1338-H1350 (1998).
19. Lorenz, J.N. & Kranias, E.G. Regulatory effects of phospholamban on cardiac function in intact mice. Am. J. Physiol. 273, H2826-H2831 (1997).
20. Maughan, D.W. et al. Altered crossbridge kinetics of permeabilized myocardium from a mouse model of Arg403Gln familial hypertrophic cardiomyopathy. Circulation 98, 1-625 (1998).
21. Rayment, I. et al. Structure of the actin-myosin complex and its implications for muscle contraction. Science 261, 58-65 (1993).
22. Sweeney, H.L. et al. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J. Biol. Chem. 269, 1603-1605 (1994).
23. Sutton, M.St.J. & Epstein, J.A. Hypertrophic cardiomyopathy: Beyond the sarcomere. N. Engl. J. Med 338, 1303-1304 (1998)
24. Welch, W.J. et al. Validation of miniature ultrasonic transit-time flow probes for measurement of renal blood flow in rats. Am. J. Physiol. 268, F175-178 (1995)
25. Wen C, et al. Validation of transonic small animal flowmeter for measurement of cardiac output and regional blood flow in the rat. J. Cardiovasc. Pharm. 27, 482-486 (1996).